Improving the Quality of Care for Patients with Atopic Dermatitis: Integrating Measurement-Based Tools Into Your Clinical PracticePremiere Date: Thursday, December 13, 2018
This activity offers CE credit for:%>
- Physicians (CME)
- Nurses (CNE)
- Pharmacists (ACPE)
- ABIM (MOC)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Thursday, December 31, 2020
Note: Credit Is No Longer Available
|Zelma C. Chiesa Fuxench, MD, MSCE (Moderator)
Assistant Professor of Dermatology
Department of Dermatology
University of Pennsylvania Perelman School of Medicine
|Stephen D. Hess, MD, PhD
President / Medical Director
Center City Dermatology
Clinical Associate in Dermatology
Department of Dermatology
Hospital of the University of Pennsylvania
|John J. Russell, MD, FAAFP
Clinical Professor, Department of Family and Community Medicine
Thomas Jefferson University Sydney Kimmel Medical College
Department Chair, Department of Family Medicine
Program Director, Family Medicine Residency
|Jonathan I. Silverberg, MD, PhD, MPH
Associate Professor of Dermatology
Director of Clinical Research and Contact Dermatitis
George Washington University School of Medicine and Health Sciences
Attitudes about atopic dermatitis are evolving with the emergence of new and effective treatments. With the average dermatologist having not enjoyed caring for patients with AD for decades, there is little to no consensus in current practice about validated tools to assess and monitor the severity of the diseases and no consistent use of diagnostic or assessment tools. This lack of knowledge and education leads to confusion, poor recognition, and absence of assessment of AD severity.
The use of patient-reported outcomes such as the Patient-Oriented Eczema Measure (POEM) are often underused in clinical practice despite being simple, valid, repeatable, and easy to interpret. The use of tools such as POEM is important to capture the impact of AD on health-related quality of life.
In this CME Outfitters Live and On Demand, expert faculty will discuss diagnostic assessment and measurement of symptom severity in AD including patient-reported outcomes, with the goal of educating clinicians regarding tools for diagnosis and assessment that can be integrated into their clinical practice.
At the end of this CE activity, participants should be able to:
- Apply the Hanifin Rajka criteria and/or the American Academy of Dermatology (AAD) criteria to facilitate the diagnosis of AD in clinical practice
- Incorporate the POEM assessment scale into clinical practice to monitor disease severity and response to treatment.
- Document the utilization of clinical assessment tools and results form their use in patients' charts.
The following learning objectives pertain only to those requesting CNE or CPE credit:
- Summarize the Hanifin Rajka criteria and/or the American Academy of Dermatology (AAD) criteria used to diagnose AD.
- Describe the POEM assessment scale for monitoring disease severity and response to treatment.
- Identify the tools and clinical assessment results that should be documented in patients' charts.
Supported by an educational grant form Sanofi Genzyme and Regeneron Pharmaceuticals.
Dermatologists, allergists, primary care physicians, physician assistants, nurse practitioners, nurses, and pharmacists.
CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CME Outfitters, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CNE Credit (Nurses):
Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1.5 contact hours.
Note to Nurse Practitioners and Clinical Nurse Specialists: the content of this activity pertains to pharmacology. Earn up to 1.5 contact hours of pharmacotherapeutic contact hours.
Note to Nurse Practitioners: Nurse Practitioners can apply for AMA PRA Category 1 Credit™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.5 contact hours (0.15 CEUs) Universal Activity Number:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Note to Physician Assistants: AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 CreditTM from organizations accredited by the Accreditation Council for Continuing Medical Education.
MIPS Improvement Activity: This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Chiesa Fuxench discloses that she serves on the Advisory Board for Sanofi Genzyme and Regeneron Pharmaceuticals.
Dr. Hess discloses he is on the Speakers Bureau for Celgene Corporation; Janssen Pharmaceuticals, Inc.; Pfizer Inc.; Sanofi Genzyme and Regeneron Pharmaceuticals; and Sun Pharmaceutical Industries Ltd. He is a consultant for Celgene Corporation; Janssen Pharmaceuticals, Inc.; and Verrica Pharmaceuticals. He is a stock shareholder (directly purchased) for Aclaris Therapeutics, Inc; Celgene Corporation; and Verrica Pharmaceuticals.
Dr. Russell discloses he is on the Speakers Bureau and a consultant for Sanofi.
Dr. Silverberg reports that he receives grants from GlaxoSmithKline and receives research support for Sanofi Genzyme and Regeneron Pharmaceuticals. He is a consultant for AbbVie Inc.; Anaptys Bio, Inc; Asana BioSciences, LLC; Dermavant Sciences, Inc.; Eli Lilly and Company; Incyte Corporation; Galderma; GlaxoSmithKline; Glenmark Pharmaceutical Inc.; Kiniksa Pharmaceuticals; LEO Pharma Inc.; Menlo Therapeutics; Pfizer Inc.; Realm Therapeutics, Inc.; and Sanofi Genzyme and Regeneron Pharmaceuticals .
Jeffrey Helfand, DO, MS (peer reviewer) has no disclosures to report.
Mae Ochoa, RPh (Peer Reviewer) has no disclosures to report.
Kate Nelson, PhD (planning committee) has no disclosures to report.
Jan Perez (planning committee) has no disclosures to report.
Sharon Tordoff (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).